882TiP Subcutaneous vs intravenous nivolumab in patients with melanoma following complete resection
Ascierto, P.A., Mohr, P., Dronca, R., Harris, S., Wilson, M., Gurm, B., Howansky, M., Ng, W-T., Ravimohan, S., Vezina, H., Pe Benito, M., Gurman, P.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Ascierto, P.A., Del Vecchio, M., Merelli, B., Gogas, H., Arance Fernandez, A.M., Dalle, S., Cowey, C.L., Schenker, M., Grob, J.J., Chiarion Sileni, V., Marquez-Rodas, I., Butler, M.O., Di Giacomo, A.M., Pe Benito, M., Soomro, R., Askelson, M., Weber, J.S., Larkin, J.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article